Compare Verizon Communications Inc (VZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verizon Communications Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Verizon Communications Inc trades at $41.83 (market cap $192.57B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Verizon Communications Inc is far larger — about 19× State Street SPDR S&P Biotech ETF's market cap, and Verizon Communications Inc pays a 6.11% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Verizon Communications Inc for 109 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VZ | XBI | |
|---|---|---|
Market Cap | $192.57B | $10.11B |
Volume | 20,940,094 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $51.45 | $169.55 |
52-Week Low | $38.40 | $104.99 |
Typical Hold Time | 109 Days | 38 Days |
Enterprise Value | $379.28B | — |
Dividend Yield | 6.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Verizon (VZ) trades at $41.65, down 9% today, with bearish technical signals but solid fundamentals. The stock shows consistent earnings beats (Q4 2025-Q2 2026) and maintains strong cash flow ($37.1B operating cash flow in 2025). Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand coverage and the election of Charles Phillips to the board (GlobeNewsWire, September 29, 2026).
Outlook: Attractive for income investors with a 6.8% dividend yield and stable cash flow, but high debt ($144B total debt) and competitive pressures pose risks. Analyst consensus price target of $48.17 suggests 16% upside, though technical indicators remain bearish near-term.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
